Skip to main content

Table 7 Deaths during the RENEW study

From: Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study

Count

Age (years)/

Form

Baseline

Cause(s)

Study phase

Treatment

Cumulative

 

gender

of MS

EDSS

  

related?

dose mg/m2

1

51/F

SPMS

7

Pneumonia

Treatment

No

91.3

2

43/F

SPMS

6

Decreased ejection fraction,

Treatment

Probable

96.8

cardiomyopathy, congestive heart

failure

3

50/F

SPMS

8.5

Pulmonary embolism

Treatment

No

12.2

4

57/M

SPMS

7

Road traffic accident

Annual follow-up

No

99.7

5

57/M

SPMS

6

Prostate cancer

Treatment

No

Unknown

6

49/M

SPMS

6.5

Cerebrovascular accident, carotid

Annual follow-up

Possible

119.4

artery occlusion

7

57/M

PRMS

7

Pulmonary edema

Annual follow-up

Unknown

109.5

8

55/F

SPMS

6.5

Pulmonary embolism

Annual follow-up

No

67.7

9

51/F

RRMS

4

Acute meningitis

Treatment

Possible

11.9

10

68/M

SPMS

7.5

Respiratory failure

Treatment

No

11.1

11

37/F

SPMS

9

Cardiopulmonary arrest

Treatment

No

18.4

12

44/F

SPMS

7

Septic shock

Treatment

Possible

81.9

  1. EDSS=Expanded Disability Status Scale; F=female; M=male; MS=multiple sclerosis; PRMS=progressive relapsing multiple sclerosis; RENEW=Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis; SPMS=secondary progressive multiple sclerosis.